Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn's disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trial

Louis, Édouard; Resche‐Rigon, Matthieu; Laharie, David; Satsangi, Jack; S. Ding, Nik; Siegmund, Britta; D’Haens, Geert; Picon, Laurence; Bossuyt, Peter; Vuitton, Lucine; M. Irving, Peter; Viennot, Stéphanie; A Lamb, Christopher; Pollok, Richard; Baert, Filip; Nachury, Maria; Fuméry, Mathurin; Gilletta, Cyrielle; Almér, Sven; Ben‐Horin, Shomron; Bouhnik, Yoram; Colombel, Jean‐Frédéric; Hertervig, Erik; M. Andrews, Jane; Sparrow, Miles; W. Leong, Rupert; J. Connor, Susan; Radforth-Smith, Graham; De Cruz, Peter; Preiß, J.; Stallmach, Andrea; Liceni, Thomas; Grip, O; Halfvarson, Jonas; Durai, Dharmaraj; Cummings, Fraser; Seilinger, Christian; Parkes, Miles; Lindsay, James; Lambrecht, Guy; Van Hootegem, Philippe; Rahier, Jean‐François; Dewitte, Marie; Hébuterne, Xavier; Chanteloup, Elise; Altwegg, Romain; Nancey, Stéphane; Bouguen, Guillaume; Pineton de Chambrun, Guillaume; Poullenot, F.; Roblin, Xavier

doi:10.1016/s2468-1253(22)00385-5

Public

Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn's disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trial

Published in The Lancet. Gastroenterology & hepatology • Jan 11, 2023

Authors:

Édouard Louis

Matthieu Resche‐Rigon

David Laharie

Abstract

BACKGROUND: The combination of infliximab and immunosuppressant therapy is a standard management strategy for patients with Crohn's disease. Concerns regarding the implications of long-term combination therapy provided the rationale for a formal clinical trial of treatment de-escalation. Our aim was...

Subject

Infliximab

Medicine

Randomized controlled trial

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!